OBSERVATIONALACTIVE NOT RECRUITINGNCT02994719

Gait Pattern Analysis in Neurological Disease

The purpose of this study is to investigate whether speed-dependent measures of gait (so called gait signatures) can be identified in patients with neurological conditions that affect gait, particularly in subjects with parkinsonian disorders.

Locally preserved from ClinicalTrials.govOpen ClinicalTrials.govlast source update 2026-07-08

What this record can show

Protocol only - no registry results posted

This locally preserved record separates the registered protocol from source-reported registry results. Neither is a treatment recommendation.

Registry facts

Study at a glance

Phase: Not reported
Enrollment: 120 (ESTIMATED)
Start date: 2016-03-01
Sponsor: Beth Israel Deaconess Medical Center
Design: Not reported
Locations: 1
Results record: Not present in registry snapshot

This study aims to determine whether the gait patterns, modeled as gait signatures, in these subjects differ in predictable and quantifiable ways from those of age- and sex-matched healthy controls (cross sectional data). This will be conducted by asking 40 Parkinsonian disorder subjects and 40 age-matched healthy control subjects to walk 9 trials over an 18 ft walkway embedded with pressure sensors at baseline, self-selected slower and faster speeds. In addition, the protocol aims to investigate whether clusters of gait patterns can be identified within subgroups of individuals with parkinsonian disorders with varying co-morbidities or treatment conditions as well as patients with ataxia or huntington's disease. For this aim an additional 20 Parkinsonian disorder subjects need to be recruited. Patients with parkinsonism as defined by UK PD Brain Bank Criteria (n=60), subjects with acquired or inherited ataxic syndromes (n=10), age- and sex matched controls (n=40) and young healthy controls (n=30) will be recruited. The cohort of young healthy controls serves to validate gait analysis modeling.There is an optional second visit in the protocol during which approximately 20 subjects with Parkinsonian disorders, who are willing to come off antiparkinson medication and if applicable, off both medication and deep brain stimulation, are asked to walk an additional 9 trials. The PD and older healthy control subjects have to option to be followed longitudinally.

Linked local records

Related local records

Local links use governed condition terms or exact source-reported intervention names. They are navigation candidates, not efficacy claims.

Conditions

Parkinson Disease

Cannabinoids and active compounds

No governed compound link was found.

Medicines

No exact medicine-name link was found.

Interventions

What was registered

DRUG

Anti-Parkinson medication

During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.

Carbidopa/levodopa · pramipexole · ropinirole · amantadine · tolcapone · entacapone

DEVICE

Deep Brain Stimulation

During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.

Eligibility

Population and criteria

Sex: ALL
Minimum age: 18 Years
Maximum age: 85 Years
Healthy volunteers: Accepted

Study population

Subjects with Parkinsonism as defined by UK PD Brain Bank Criteria. The study population includes subjects with Parkinson's Disease and may also include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration. Subgroups include subjects with ataxia and huntington's disease and control subjects without known neurological disease.

Inclusion criteria

Age 18-85 (for both healthy and affected subjects).
Presence of at least 2 of the following: bradykinesia, rest tremor, rigidity, postural instability (UK PD Brain Bank Criteria) (Affected subjects only).
Montreal Cognitive Assessment will be employed to determine whether subjects will need the assent of a legally authorized representative. Subjects with MOCA ≤ 21 will be consented only with the assent of the subject and informed consent of the authorized legal representative (Affected subjects only).
These may include subjects who may have indeterminate parkinsonism, when it is not clear whether they have idiopathic Parkinson's Disease versus one of the Atypical Parkinsonisms, such as Vascular Parkinsonism, Multiple System Atrophy, Progressive Supranuclear Palsy, Normal Pressure Hydrocephalus or Corticobasal Degeneration (Affected subjects only).
Subjects with assistive devices will be eligible for the study and may use them during the study (Affected subjects only).
Absence of complaints regarding difficulty walking such as arthritic pain, fatigue during walking or slowness of walking (Healthy subjects only).

Exclusion criteria

Presence of alternative explanation for parkinsonism such as head trauma, drug-induced parkinsonism (affected subjects only).
Currently being treated for major medical illness requiring recent hospitalization (\<14 days) (for both healthy and affected subjects).
Currently participating in another clinical study with an intervention arm (for both healthy and affected subjects).
Inability to consent due to cognitive impairment and absence of legally authorized representative (for both healthy and affected subjects).

primary outcomes

primary measures

Gait speed

Time frame: through study completion, an average of 1 year, with option of PD and older healthy controls to be followed longitudinally for the course of the disease